Key Takeaways
- A year of extraordinary headwinds, but margins held: Revenue fell ~19% as pricing dropped 25–30% and volumes softened, yet gross margin expanded sharply in H2 after high-cost inventory was liquidated by August.
- Q4 gross margin hit 42%, and management says it is sustainable: The company bought raw materials cheap, did not pass the full benefit to customers, and sees the same pricing carrying into Q1 with no risk of reduction barring a monsoon or geopolitical shock.
- The parent is doubling down on India as a manufacturing hub: SCC Japan wants India to be "as big a manufacturing hub in time to come," with land acquired at Bhavnagar and Dahej, environmental clearance applied for, and a pipeline of proprietary products under study.
- Recovery is volume-led and back-ended: Domestic demand is expected to revive quickly on a good monsoon forecast, but export recovery, especially from LatAm, is more a FY26 story than FY25.
- What to watch next quarter: Whether the monsoon materializes as forecast and triggers the domestic volume uptick, any stabilization in LatAm order positions, and progress on environmental clearance for Dahej.
The FY24 Shock: What Happened
- Pricing collapsed across the generic portfolio: Prices of key active ingredients fell 25–30% across the board, driven by excess supply, destocking by global manufacturers, and elevated channel inventory. Specialty molecules saw only a minor ~2% price decline.
- Volumes took a hit too: Overall volumes degrew approximately 8–9%, with specialty volumes largely maintained but generic molecules losing ground in both export and domestic markets. The ~19% revenue decline was split roughly equally between price and volume.
- Weather compounded the damage: Erratic weather and lower-than-average rainfall from El Nino hurt Kharif demand; low reservoir water levels then squeezed the Rabi season. In LatAm, droughts and excessive rains in Brazil reduced crop yields and agrochemical demand.
- Exports bore the brunt: Significant pricing pressure, global destocking, and elevated inventory levels hit exports hard. The major drop came from Latin America and is not expected to be fully compensated by the ramp-up of one product at Bhavnagar.
- Collections held up better than revenue: Despite a 19% revenue decline, the reduction in collections was only about 9%, reflecting strong discipline on receivables.
Chetan Shah: "So see, our first objective is not to match the numbers or surpass the numbers. What we are concentrating on is to increase the volumes of our products. Because as you may have noticed in order to compare the last year's numbers, the prices itself have dropped 25% or so, 25%, 30% in some products, even more maybe."
Margin Story: The Inventory Reset Payoff
- High-cost inventory was wiped out by August: The company rapidly liquidated its high-cost raw material inventory by the end of Q2, allowing it to purchase low-cost material from Q3 onward. That low-cost material was churned into brands and sold at good contribution.
- Q4 gross margin jumped to 42%: This compares to 31% in Q4 FY23, which was still carrying high-cost inventory. Management says Q2, Q3, and Q4 margins are now at normalized levels, with no extraordinary positive events, only the removal of the past negative.
- The company did not pass on the full cost benefit: In Q4, raw materials were bought at lower prices, giving a cost advantage. Prices to the market were reduced, but not to the full extent of the procurement savings, widening the gross margin.
- Pricing stability is the bet: As of the call date, Q4 pricing had not changed and was being carried forward into Q1, accepted by the marketplace. Management sees no risk of reducing prices in coming months unless something drastic happens with the monsoon or geopolitics.
- Procurement tailwind continues: Purchasing done in Q4 for Q1 and Q2 production gave a tremendous benefit on costing, and the company does not see price erosion from this.
Chetan Shah: "As of date, we don't intend to but we'll have to see the competition... Fortunately, we, at Sumitomo products, we don't have a high level of inventory in the market, which is another very good sign for us. So how much the competition will drop, we cannot judge as fully as of today. But what we have seen in Q4 and in the first month of Q1, is that it is not affecting us significantly. So I think it would be safe to presume and we hope that we don't have to reduce any more prices."
Manufacturing Expansion: The Parent's India Bet
- SCC Japan wants India as a major manufacturing hub: The parent company's commitment to India manufacturing is "unwavering," per the India-based SCC executive. No other sites are being looked at; India is the priority.
- Bhavnagar plant is at full production: Last year, 40–50% of capacity was sold for export; the current year target is 100% export of production capacity. A new 20-acre land parcel has been acquired at Bhavnagar, with meaningful contribution expected in 12–18 months.
- Tarapur plant lost a year: The new plant is ready for commercial production and materials have been produced, but global demand conditions and inventory levels at affiliates prevented conversion into revenue beyond small trial orders. Full production is now expected only from FY25–26. "We have lost out on this revenue in '24-'25."
- Dahej is the next big one: A 50-acre land parcel is already in possession, and an application for environmental clearance has been submitted, with clearance expected by end of this calendar year. The product pipeline has been identified and is under study by the parent company. Commercial production is 18–24 months away after clearance and product approval.
- Capex will be funded entirely from internal accruals: The company is in a position to fund all capex for the new site, whether next year or in 3–4 years, from its own cash generation, with no external borrowing.
- IT chemicals exploration is at a very preliminary stage: SCC Japan's IT department has made a preliminary inquiry about what can be done in the IT chemicals sector in India. The company does not yet have the skill set internally and will need to create it. The plan is first to have product entry in India, then think about manufacturing, a long-term plan.
Masanori Uzawa: "First of all, I would like to say the Sumitomo Chemical Tokyo's commitment to the India manufacturing is unwavering. So we have a strong commitment and that will never change."
Demand Recovery: Domestic First, Exports Later
- Domestic sentiment is cautiously better: Compared to last year, sentiments are good and the monsoon forecast is favorable. However, there is no significant pushback or significant demand yet; the trade is waiting and watching how the monsoon plays out.
- IMD forecast is a tailwind: Above-normal rainfall predicted for this year would significantly benefit agriculture and the agrochemical sector. Domestic demand is expected to revive very quickly if the forecast holds.
- Export recovery is more back-ended: International business revival may take more time, though some stability in order positions is visible. Full recovery is more a FY26 story than FY25, and it is volume-led.
- LatAm remains a question mark: Weather seems challenging from early reports, but the season has not started yet. Feedback from sources including the group company shows optimism. Management will know more in 30–45 days.
- Volume growth is the priority, not revenue comparisons: Because prices have dropped 25–30%, turnover can only reach last year's level if volumes increase. The company is not targeting a specific revenue number but is focused on driving volumes.
Product Pipeline & Portfolio Shift
- Three new registrations received, targeting Kharif: One for cotton, one for rice, one for vegetables covering insects, mites, and diseases in paddy. All are 9(3) proprietary products with unique combinations, and will enter the market in the next few weeks.
- Six products launched in FY24: Three herbicides, one insecticide, and two fungicides. Last year was not the best for new products due to weather, pest, and crop challenges. The aspiration is 8–10% contribution from new products if the season is normal.
- Specialty molecules are the strategic focus: The endeavor is for specialty molecules to take a significant leap in growth and overall revenue, growing higher than the market growth rate. The company is not looking at products that could become off-patent or commodity where margins could be under pressure.
- Parent company pipeline under evaluation: In the next few quarters, the company expects to arrive at a decision on new products from the parent. The Dahej plant will potentially house at least two brand-new products from SCC Japan.
- Barrix acquisition adds environmentally friendly technologies: Consolidated from 15 December 2023, with sales of ~INR10–12 crores for ~105 days. Expected to show very good growth year-on-year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin sustainability | Q4 pricing carried into Q1, accepted by market; no risk of price reduction seen | Barring monsoon failure or geopolitical shock |
| Bhavnagar plant export ramp-up | 100% of production capacity exported (up from 40–50%) | FY25 |
| Tarapur plant full production | 5 new molecules to reach fullest extent of commercial production | FY26 (delayed from FY25) |
| Dahej environmental clearance | Application submitted; clearance expected | End of calendar year 2024 |
| Dahej commercial production | 18–24 months after EC clearance and parent product approval | FY26–FY27 |
| New Bhavnagar land contribution | Meaningful contribution from 20-acre expansion | 12–18 months |
| Green energy capex | INR25 crores to become 100% green power generation company | End of FY25 |
| New product contribution aspiration | 8–10% of revenue from new products | If monsoon is normal |
| Capex funding | All capex funded from internal accruals, no external borrowing | Ongoing |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹674 cr, up 3% YoY and 24% QoQ |
| Gross margin | 41.7%, up 1,042 bps YoY and 199 bps QoQ |
| EBITDA | ₹140 cr, up 74% YoY and 113% QoQ |
| EBITDA margin | 20.8%, up 843 bps YoY |
| Profit after tax | ₹110 cr, up 52% YoY and 101% QoQ |
| PAT margin | 16.3%, up 523 bps YoY |
| FY24 full-year revenue | ₹2,844 cr, down 19% YoY from ₹3,511 cr |
| FY24 full-year EBITDA margin | 16.7%, vs 19% in FY23 |
| FY24 full-year PAT | ₹370 cr, vs ₹502 cr in FY23 |
| Domestic revenue share (FY24) | ~80% of total revenue, export ~20% |
| Insecticides share (FY24) | ~41% of total revenue |
| Herbicides share (FY24) | ~22% of total revenue |
| PGR share (FY24) | ~10% of total revenue |
| Fungicides share (FY24) | ~8% of total revenue |
| Cash and cash equivalents | ₹1,207 cr as on 31st March 2024, after interim dividend payment |
| Net working capital reduction | 33 days as on March 2024 vs March 2023 |
| Collections (FY24) | ₹3,325 cr, down 9% vs ₹3,676 cr in FY23, against 19% revenue decline |
| Specialty volume degrowth (FY24) | ~8-9% overall, with minimal price decline of ~2% |
| New product contribution aspiration | 8-10% of revenue from products launched in the last 2-3 years |
| Barrix consolidated sales | ₹10-12 cr for ~105 days from 15 Dec 2023 |
| Bhavnagar new plant capacity utilization (FY24) | 40-60% commercialization achieved, 100% expected in FY25 |
| Maintenance and other capex planned (FY25) | ₹53 cr, including ₹25 cr for green energy to achieve 100% captive power |
| Next capex cycle estimate | ₹250-300 cr to start the new Dahej site, funded through internal accruals |